Study of pegcetacoplan safety and effectiveness in adolescents aged 12-17 with paroxysmal nocturnal hemoglobinuria

2 1 1 1

What is this study about?

This study focuses on Paroxysmal Nocturnal Hemoglobinuria, a rare blood disorder where the immune system attacks and destroys red blood cells. The study will evaluate a medication called pegcetacoplan, given as a solution that is injected under the skin. This medicine works by helping to protect red blood cells from being destroyed by the body’s immune system.

The purpose of this research is to understand how the medication works in young patients aged 12-17 years and to determine if it is safe and effective for treating their condition. The study will look at how the medication affects various aspects of the blood, including hemoglobin levels (a protein that carries oxygen in red blood cells) and other markers that show how well the treatment is working.

Participants will receive treatment with pegcetacoplan for 16 weeks, during which they will need regular check-ups to monitor their health and how well the medication is working. The medication will be given through injections under the skin. Throughout the study, doctors will closely monitor the participants’ blood test results and any side effects that may occur. The total study duration may extend up to 52 weeks to gather long-term safety and effectiveness information.

1 Initial treatment phase

The treatment begins with pegcetacoplan (ASPAVELI), given as a solution under the skin (subcutaneous use)

The medication will be administered at a dose of 1,080 mg

You or your caregiver will need to learn how to give the medication through subcutaneous injection

If not already vaccinated, you will receive vaccines against specific bacteria (Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae) within 14 days of starting treatment

2 First 16 weeks of treatment

Regular blood tests will monitor your response to treatment

The tests will measure:

– Hemoglobin levels (a protein that carries oxygen in your blood)

– LDH levels (an indicator of cell damage)

– Red blood cell counts

Your overall health and any side effects will be monitored

3 Extended treatment phase

Treatment continues for up to 52 weeks

Regular monitoring of your blood tests continues

Additional assessments include:

– Complement system activity (part of your immune system)

– Quality of life measurements

– Number of blood transfusions needed, if any

Your overall health and any side effects continue to be monitored

4 Final evaluation

Assessment of your response to treatment over the full 52-week period

Final blood tests and health evaluations

Review of any side effects or complications that occurred during treatment

Who Can Join the Study?

Age must be between 12 and 17 years old at the start of the study
Must weigh at least 20 kilograms
Must have a body mass index (BMI) below the 95th percentile for their age
Must have confirmed diagnosis of PNH through special blood testing showing specific cell populations above 10%
Must have either:
- Never received complement inhibitor treatment with low blood hemoglobin and high LDH levels, or
- Currently be on stable complement inhibitor treatment with low blood hemoglobin
Blood test requirements:
- Platelet count above 75,000 per cubic millimeter
- Neutrophil count (type of white blood cell) above 1,000 per cubic millimeter
Must be willing and able to self-administer the medication or have a caregiver who can do it
Must be vaccinated against specific bacteria (Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae) or agree to receive vaccines within 14 days of starting treatment
For females who can become pregnant: must have negative pregnancy tests and use approved birth control methods during the study and for 90 days after
For sexually mature males: must use approved birth control methods and not donate sperm during the study and for 90 days after
Must maintain stable doses of any current medications (such as blood thinners, steroids, or supplements) for specified periods before starting the study
Must be willing to provide written informed consent (and assent if appropriate) to participate in the study

Who Cannot Join the Study?

Current or recent (within 3 months) pregnancy or breastfeeding
History of severe allergic reactions to any medications
Active, uncontrolled bacterial infections
Severe liver problems (as shown by blood tests)
Major surgery in the past 3 months
Participation in other clinical trials within the last 30 days
Active cancer or cancer treatment
Severe heart conditions or uncontrolled high blood pressure
History of blood clotting disorders
Inability to follow study procedures or attend scheduled visits
Use of certain medications that might interact with the study drug
Severe kidney disease (as determined by blood tests)
Mental conditions that could affect ability to provide informed consent
Drug or alcohol abuse within the past year
Any condition that, in the opinion of the study doctor, would make participation unsafe

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Hospital Universitario 12 De Octubre	Madrid	Spain
Universitair Medisch Centrum Utrecht	Utrecht	The Netherlands
Hhvsourx Vkil djnbkxua	Barcelona	Spain

Trial status

Country	Status	Recruitment Start
Spain	Recruiting	14.10.2020
The Netherlands	Recruiting	14.10.2020

Trial locations

Investigated drugs:

Pegcetacoplan

Pegcetacoplan is a medication designed to treat paroxysmal nocturnal hemoglobinuria (PNH). It works by targeting and regulating part of the body’s complement system, which is a component of the immune system. This medication helps protect red blood cells from destruction in patients with PNH, potentially improving anemia and reducing the need for blood transfusions. It is administered under the skin (subcutaneously) and is being studied specifically in adolescent patients to understand how it works in younger populations.

Paroxysmal Nocturnal Hemoglobinuria – A rare blood disorder where the immune system attacks and destroys red blood cells. The condition occurs due to a genetic mutation that affects the protective coating of blood cells. The destruction of red blood cells happens continuously but often becomes worse during sleep, leading to the presence of dark-colored urine in the morning. The condition causes anemia and can result in fatigue, weakness, and shortness of breath. The disease typically develops in young adulthood but can occur at any age.

Trial ID:

2024-516350-22-00

Protocol code:

APL2-PNH-209

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of pegcetacoplan safety and effectiveness in adolescents aged 12-17 with paroxysmal nocturnal hemoglobinuria

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?